<DOC>
	<DOCNO>NCT00662272</DOCNO>
	<brief_summary>This study design assess safety , tolerability immunogenicity Fluzone® vaccine four dose level JVRS-100 adjuvant compare Fluzone® vaccine alone healthy adult 18-49 year age .</brief_summary>
	<brief_title>Safety Efficacy Study Fluzone® Vaccine Combined With Different Doses JVRS-100 Adjuvant</brief_title>
	<detailed_description>The purpose trial evaluate safety tolerability grade , ascend dos JVRS-100 adjuvant administer combination vaccine antigen .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>able understand study provide write informed consent age 18 49 year good general health , without significant medical history , physical examination finding , abnormal laboratory result available study duration , include plan followup visit female subject child bear potential must pregnant agree correctly use efficacious hormonal method contraception intrauterine device least 1 month study study allergy eggs component vaccine influenza vaccine within 3 year precede screen visit history severe reaction kind conventional influenza vaccine suspect immunodeficiency disorder , include leukemia , lymphoma , generalized malignancy , treatment immunosuppressive medication , include corticosteroid , alkylating agent , antimetabolite , radiation therapy history autoimmune disorder , include systemic lupus , rheumatoid arthritis , scleroderma , collagen vascular disease , multiple sclerosis , etc . Psoriasis limit cutaneous manifestation exclusion criterion . prior history anaphylaxis food , hymenoptera sting , vaccine drug transfusion blood treatment blood product , include intramuscular intravenous serum globulin within 3 month Screening Visit anticipate study period receive another vaccine within 30 day precede screen visit anticipate study period participation another clinical trial within 60 day screen visit positive serum urine pregnancy test prior vaccination plan pregnancy study period abnormality laboratory assessment seropositive HIV HCV positive HBsAg positive antinuclear antibody physical examination indicate clinically significant medical condition body temperature &gt; 38.1°C ( 100.6°F ) acute illness within 3 day prior vaccination intention travel area prior study visit Day 28 study history excessive alcohol consumption , drug abuse , significant psychiatric illness intention increase normal exercise routine , participate contact sport strenuous weight lift initiate vigorous exercise Screening Day 28 study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Flu</keyword>
	<keyword>Influenza vaccine</keyword>
	<keyword>Adjuvant</keyword>
	<keyword>Safety adjuvanted vaccine</keyword>
	<keyword>Immune response adjuvanted vaccine</keyword>
</DOC>